TNF in host resistance to tuberculosis infection

Current Directions in Autoimmunity

Volumn 11, Issue , 2010, Pages 157-179

  Quesniaux, Valerie F J ^a   Jacobs, Muazzam ^b,c   Allie, Nasiema ^b   Grivennikov, Sergei ^a,d   Nedospasov, Sergei A ^d,e   Garcia, Irene ^f   Olleros, Maria L ^f   Shebzukhov, Yuriy ^e   Kuprash, Dmitry ^d   Vasseur, Virginie ^a   Rose, Stephanie ^a   Court, Nathalie ^a   Vacher, Rachel ^a   Ryffel, Bernhard ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^e DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^f UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

CROHN DISEASE; CYTOKINE PRODUCTION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; INFECTION; INFECTION RESISTANCE; INFECTION RISK; MOUSE MUTANT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

CORYNEBACTERINEAE; MUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 77949445679     PISSN: 14222132     EISSN: 16622936     Source Type: Book Series    
DOI: 10.1159/000289204     Document Type: Review

References (140)

1. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC: Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005;293:2767-2775.
2. Gill W P, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR: A replication clock for Myco-bacterium tuberculosis. Nat Med 2009;15:211-214.
3. Flynn JL, Chan J: Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129.
4. North RJ, Jung YJ: Immunity to tuberculosis. Annu Rev Immunol 2004;22:599-623.
5. Flynn JL: Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 2004;84:93-101.
6. Cooper AM: Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009;27:393-422.
7. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, Kawakami K, Suda T, Sudo K, Nakae S, Iwakura Y, Matsuzaki G: IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007;178: 3786-3796.
8. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, Locksley RM, Haynes L, Randall TD, Cooper AM: IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-377.
9. Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, Maillet I, Jacobs M, Ryffel B, Quesniaux VF: IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Myco-bacterium tuberculosis infection. J Immunol 2007; 179:1178-1189.
10. Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, Springer B, Timmins GS, Sander P, Deretic V: Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe 2008;3:224-232.
11. Russell DG: Who puts the tubercle in tuberculosis? Nat Rev Microbiol 2007;5:39-47.
12. Bekker LG, Moreira AL, Bergtold A, Freeman S, Ryffel B, Kaplan G: Immunopathologic effects of tumor necrosis factor alpha in murine mycobacte-rial infection are dose dependent. Infect Immun 2000;68:6954-6961.
13. Ehlers S, Benini J, Held HD, Roeck C, Alber G, Uhlig S: Alphabeta T cell receptor-positive cells and inter-feron-gamma, but not inducible nitric oxide syn-thase, are critical for granuloma necrosis in a mouse model of mycobacteria-induced pulmonary immu-nopathology. J Exp Med 2001;194:1847-1859.
14. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
15. Ware CF: Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005;23:787-819.
16. Watts TH: TNF/TNFR family members in costimu-lation of T cell responses. Annu Rev Immunol 2005; 23:23-68.
17. Spahr L, Giostra E, Frossard JL, Bresson-Hadni S, Rubbia-Brandt L, Hadengue A: Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. J Hepatol 2004;41:229-234.
18. Edrees AF, Misra SN, Abdou NI: Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005;23:469-474.
19. Gommerman JL, Browning JL: Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 2003;3:642-655.
20. Fu YX, Chaplin DD: Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999;17:399-433.
21. Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL: Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 1986;83:8699-8702.
22. Nedospasov SA, Hirt B, Shakhov AN, Dobrynin VN, Kawashima E, Accolla RS, Jongeneel CV: The genes for tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse. Nucleic Acids Res 1986;14:7713-7725.
23. Chan KF, Siegel MR, Lenardo JM: Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000;13:419-422.
24. Grivennikov SI, Kuprash D V, Liu ZG, Nedospasov SA: Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: from simple paradigms to complex mechanisms. Int Rev Cytol 2006;252:129-161.
25. Pinckard JK, Sheehan KC, Arthur CD, Schreiber RD: Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol 1997; 158:3869-3873.
26. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG: Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 1998;161:2636-2641.
27. Garcia I, Guler R, Vesin D, Olleros ML, Vassalli P, Chvatchko Y, Jacobs M, Ryffel B: Lethal Myco-bacterium bovis bacillus Calmette Guerin infection in nitric oxide synthase 2-deficient mice: cell-mediated immunity requires nitric oxide synthase 2. Lab Invest 2000;80:1385-1397.
28. Eissner G, Kolch W, Scheurich P: Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15:353-366.
29. van Essen D, Kikutani H, Gray D: CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 1995;378:620-623.
30. Suzuki I, Fink PJ: Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med 1998;187:123-128.
31. Kirchner S, Boldt S, Kolch W, Haffner S, Kazak S, Janosch P, Holler E, Andreesen R, Eissner G: LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J Leukoc Biol 2004;75:324-331.
32. Harashima S, Horiuchi T, Hatta N, Morita C, Higuchi M, Sawabe T, Tsukamoto H, Tahira T, Hayashi K, Fujita S, Niho Y: Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 2001;166:130-136.
33. Rossol M, Meusch U, Pierer M, Kaltenhauser S, Hantzschel H, Hauschildt S, Wagner U: Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol 2007;179:4239-4248.
34. Kriegler M, Perez C, DeFay K, Albert I, Lu SD: A novel form of TNF/cachectin is a cell surface cyto-toxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53:45-53.
35. Akassoglou K, Probert L, Kontogeorgos G, Kollias G: Astrocyte-specific but not neuron-specific trans-membrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997;158:438-445.
36. Mueller C, Corazza N, Trachsel-Loseth S, Eugster H-P, Buhler-Jungo M, Brunner T, Imboden MA: Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo. J. Biol. Chem. 1999;274:38112-38118.
37. Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Korner H, Scheerens H, Hessel EM, Cyster JG, McEvoy LM, Sedgwick JD: Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001;15: 533-543.
38. Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, Blackshear PJ, Kontoyiannis DL, Kollias G: Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmu-nity. Eur J Immunol 2006;36:2768-2780.
39. Bean AG, Roach DR, Briscoe H, France M P, Korner H, Sedgwick JD, Britton WJ: Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162:3504-3511.
40. Kaneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, Sekikawa K, Sugawara I: Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 1999;79:379-386.
41. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ: TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-4627.
42. Zganiacz A, Santosuosso M, Wang J, Yang T, Chen L, Anzulovic M, Alexander S, Gicquel B, Wan Y, Bramson J, Inman M, Xing Z: TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest 2004;113:401-413.
43. Douni E, Alexiou M, Kollias G: Genetic engineering in the mouse: tuning TNF/TNFR expression. Methods Mol Med 2004;98:137-170.
44. Garcia I, Miyazaki Y, Marchal G, Lesslauer W, Vassalli P: High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to myco-bacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997;27:3182-3190.
45. Smith S, Liggitt D, Jeromsky E, Tan X, Skerrett SJ, Wilson CB: Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection. Infect Immun 2002;70:2082-2089.
46. -/- mice is dependent on T cells and IL-12. J Immunol 2000;165:483-492.
47. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak T W, Bloom BR: Tumor necrosis factor-alpha is required in the protective immune response against Myco-bacterium tuberculosis in mice. Immunity 1995;2: 561-572.
48. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW: Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endo-toxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
49. Roach DR, Briscoe H, Saunders B, France M P, Riminton S, Britton WJ: Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J Exp Med 2001;193:239-246.
50. Jacobs M, Brown N, Allie N, Ryffel B: Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice. Clin Immunol 2000;94:192-199.
51. Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D, Bauer J, Lassmann H, Kollias G: Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004;200:367-376.
52. Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, Murakami T, Drutskaya LN, Forster I, Clausen BE, Tessarollo L, Ryffel B, Kuprash DV, Nedospasov SA: Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity 2005;22:93-104.
53. Tumanov A, Kuprash D, Lagarkova M, Grivennikov S, Abe K, Shakhov A, Drutskaya L, Stewart C, Chervonsky A, Nedospasov S: Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity 2002;17:239-250.
54. Kindler V, Sappino A P, Grau GE, Piguet PF, Vassalli P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-740.
55. Guler R, Olleros ML, Vesin D, Parapanov R, Garcia I: Differential effects of total and partial neutralization of tumor necrosis factor on cell-mediated immunity to Mycobacterium bovis BCG infection. Infect Immun 2005;73:3668-3676.
56. Eugster H P, Muller M, Karrer U, Car BD, Schnyder B, Eng VM, Woerly G, Le Hir M, di Padova F, Aguet M, Zinkernagel R, Bluethmann H, Ryffel B: Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice. Int Immunol 1996;8:23-36.
57. Bopst M, Garcia I, Guler R, Olleros ML, Rulicke T, Muller M, Wyss S, Frei K, Le Hir M, Eugster HP: Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001;31:1935-1943.
58. Adams LB, Mason CM, Kolls JK, Scollard D, Krahenbuhl JL, Nelson S: Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovi-rus. J Infect Dis 1995;171:400-405.
59. Clay H, Volkman HE, Ramakrishnan L: Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008;29:283-294.
60. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN: Macrophage and T cell dynamics during the development and disintegration of myco-bacterial granulomas. Immunity 2008;28:271-284.
61. Kuprash D V, Tumanov AV, Liepinsh DJ, Koroleva E P, Drutskaya MS, Kruglov AA, Shakhov AN, Southon E, Murphy WJ, Tessarollo L, Grivennikov SI, Nedospasov SA: Novel tumor necrosis factor-knockout mice that lack Peyer's patches. Eur J Immunol 2005;35:1592-1600.
62. Liepinsh DJ, Grivennikov SI, Klarmann KD, Lagarkova MA, Drutskaya MS, Lockett SJ, Tessarollo L, McAuliffe M, Keller JR, Kuprash DV, Nedospasov SA: Novel lymphotoxin alpha (LTalpha) knockout mice with unperturbed tumor necrosis factor expression: reassessing LTalpha biological functions. Mol Cell Biol 2006;26:4214-4225.
63. Alexopoulou L, Pasparakis M, Kollias G: Complementation of lymphotoxin alpha knockout mice with tumor necrosis factor-expressing transgenes rectifies defective splenic structure and function. J Exp Med 1998;188:745-754.
64. Schluter D, Kwok LY, Lutjen S, Soltek S, Hoffmann S, Korner H, Deckert M: Both lymphotoxin-alpha and TNF are crucial for control of Toxoplasma gon-dii in the central nervous system. J Immunol 2003; 170:6172-6182.
65. Liu JQ, Bai XF, Shi FD, Xiao BG, Li HL, Levi M, Mustafa M, Wahren B, Link H: Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99. Int Immunol 1998;10:1139-1148.
66. Marino M W, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, Jungbluth A, Wada H, Moore M, Williamson B, Basu S, Old LJ: Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997;94:8093-8098.
67. Olleros ML, Guler R, Corazza N, Vesin D, Eugster H P, Marchal G, Chavarot P, Mueller C, Garcia I: Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 2002;168:3394-3401.
68. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, Kirschner DE, Huang L, Flynn J, Chan J: Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008;76:916-926.
69. Olleros ML, Guler R, Vesin D, Parapanov R, Marchal G, Martinez-Soria E, Corazza N, Pache JC, Mueller C, Garcia I: Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis infections. Am J Pathol 2005;166:1109-1120.
70. Florido M, Appelberg R: Characterization of the deregulated immune activation occurring at late stages of mycobacterial infection in TNF-deficient mice. J Immunol 2007;179:7702-7708.
71. Flory CM, Hubbard RD, Collins FM: Effects of in vivo T lymphocyte subset depletion on mycobacterial infections in mice. J Leukoc Biol 1992;51:225-229.
72. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL: Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999;162: 5407-5416.
73. Kamath AB, Woodworth J, Xiong X, Taylor C, Weng Y, Behar SM: Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection. J Exp Med 2004;200:1479-1489.
74. Khader SA, Cooper AM: IL-23 and IL-17 in tuberculosis. Cytokine 2008;41:79-83.
75. Lockhart E, Green AM, Flynn JL: IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006;177:4662-4669.
76. Hamada S, Umemura M, Shiono T, Tanaka K, Yahagi A, Begum MD, Oshiro K, Okamoto Y, Watanabe H, Kawakami K, Roark C, Born WK, O'Brien R, Ikuta K, Ishikawa H, Nakae S, Iwakura Y, Ohta T, Matsuzaki G: IL-17A produced by gam-madelta T cells plays a critical role in innate immunity against Listeria monocytogenes infection in the liver. J Immunol 2008;181:3456-3463.
77. Junqueira-Kipnis AP, Kipnis A, Jamieson A, Juarrero MG, Diefenbach A, Raulet DH, Turner J, Orme IM: NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol 2003;171:6039-6045.
78. Chackerian A, Alt J, Perera V, Behar SM: Activation of NKT cells protects mice from tuberculosis. Infect Immun 2002;70:6302-6309.
79. Gansert JL, Kiessler V, Engele M, Wittke F, Rollinghoff M, Krensky AM, Porcelli SA, Modlin RL, Stenger S: Human NKT cells express granulysin and exhibit antimycobacterial activity. J Immunol 2003;170:3154-3161.
80. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, Hurwitz R, Kursar M, Bonneville M, Kaufmann SH, Schaible UE: Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci U S A 2004;101:10685-10690.
81. Zajonc DM, Ainge GD, Painter GF, Severn WB, Wilson IA: Structural characterization of mycobac-terial phosphatidylinositol mannoside binding to mouse CD1d. J Immunol 2006;177:4577-4583.
82. Munoz S, Hernandez-Pando R, Abraham SN, Enciso JA: Mast cell activation by Mycobacterium tuberculosis: mediator release and role of CD48. J Immunol 2003;170:5590-5596.
83. Carlos D, de Souza Junior DA, de Paula L, Jamur MC, Oliver C, Ramos SG, Silva CL, Faccioli LH: Mast cells modulate pulmonary acute inflammation and host defense in a murine model of tuberculosis. J Infect Dis 2007;196:1361-1368.
84. Jacobs M, Marino M W, Brown N, Abel B, Bekker LG, Quesniaux VJ, Fick L, Ryffel B: Correction of defective host response to Mycobacterium bovis BCG infection in TNF-deficient mice by bone marrow transplantation. Lab Invest 2000;80:901-914.
85. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N, et al: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81:641-650.
86. Chan J, Xing Y, Magliozzo RS, Bloom BR: Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992;175:1111-1122.
87. Sturgill-Koszycki S, Schaible UE, Russell DG: Mycobacterium-containing phagosomes are accessible to early endosomes and reflect a transitional state in normal phagosome biogenesis. EMBO J 1996;15:6960-6968.
88. Russell DG, Dant J, Sturgill-Koszycki S: Myco-bacterium avium-and Mycobacterium tuberculosis-containing vacuoles are dynamic, fusion-competent vesicles that are accessible to glycosphingolipids from the host cell plasmalemma. J Immunol 1996; 156:4764-4773.
89. Mwandumba HC, Russell DG, Nyirenda MH, Anderson J, White SA, Molyneux ME, Squire SB: Mycobacterium tuberculosis resides in nonacidified vacuoles in endocytically competent alveolar mac-rophages from patients with tuberculosis and HIV infection. J Immunol 2004;172:4592-4598.
90. Xu S, Cooper A, Sturgill-Koszycki S, van Heyningen T, Chatterjee D, Orme I, Allen P, Russell DG: Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected mac-rophages. J Immunol 1994;153:2568-2578.
91. Ehlers S, Kutsch S, Benini J, Cooper A, Hahn C, Gerdes J, Orme I, Martin C, Rietschel ET: NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads. Immunology 1999;98:313-323.
92. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G: TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-inde-pendent pathways. J Immunol 2001;166: 6728-6734.
93. Flynn JL, Chan J: Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 2003;15:450-455.
94. 2+ signaling and phagosome maturation in human macrophages via specific inhibition of sphingosine kinase. J Immunol 2003;170:2811-2815.
95. Malik ZA, Iyer SS, Kusner DJ: Mycobacterium tuberculosis phagosomes exhibit altered calmodu-lin-dependent signal transduction: contribution to inhibition of phagosome-lysosome fusion and intra-cellular survival in human macrophages. J Immunol 2001;166:3392-3401.
96. Malik ZA, Denning GM, Kusner DJ: Inhibition of Ca2+ signaling by Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and increased survival within human mac-rophages. J Exp Med 2000;191:287-302.
97. Deretic V: Autophagy, an immunologic magic bullet: Mycobacterium tuberculosis phagosome maturation block and how to bypass it. Future Microbiol 2008;3:517-524.
98. Jayachandran R, Sundaramurthy V, Combaluzier B, Mueller P, Korf H, Huygen K, Miyazaki T, Albrecht I, Massner J, Pieters J: Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. Cell 2007;130:37-50.
99. MacMicking JD, Taylor GA, McKinney JD: Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003;302:654-659.
100. Singh SB, Davis AS, Taylor GA, Deretic V: Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006;313:1438-1441.
101. MacMicking JD: Immune control of phagosomal bacteria by p47 GTPases. Curr Opin Microbiol 2005;8:74-82.
102. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-1773.
103. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL: An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998;282:121-125.
104. Lammas DA, Stober C, Harvey CJ, Kendrick N, Panchalingam S, Kumararatne DS: ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Immunity 1997;7:433-444.
105. Kusner DJ, Barton JA: ATP stimulates human mac-rophages to kill intracellular virulent Mycobacterium tuberculosis via calcium-dependent phagosome-lys-osome fusion. J Immunol 2001;167:3308-3315.
106. Fairbairn IP, Stober CB, Kumararatne DS, Lammas DA: ATP-mediated killing of intracellular mycobac-teria by macrophages is a P2X(7)-dependent process inducing bacterial death by phagosome-lysosome fusion. J Immunol 2001;167:3300-3307.
107. Humphreys BD, Dubyak GR: Modulation of P2X7 nucleotide receptor expression by pro-and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol 1998;64:265-273.
108. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, Modlin RL, Brinkmann V, Kaufmann SH: Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003;9:1039-1046.
109. Feng CG, Scanga CA, Collazo-Custodio CM, Cheever AW, Hieny S, Caspar P, Sher A: Mice lacking myeloid differentiation factor 88 display profound defects in host resistance and immune responses to Mycobacterium avium infection not exhibited by Toll-like receptor 2 (TLR2)-and TLR4-deficient animals. J Immunol 2003;171:4758-4764.
110. Fremond CM, Yeremeev V, Nicolle DM, Jacobs M, Quesniaux VF, Ryffel B: Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest 2004;114: 1790-1799.
111. Drennan MB, Nicolle D, Quesniaux VJ, Jacobs M, Allie N, Mpagi J, Fremond C, Wagner H, Kirschning C, Ryffel B: Toll-like receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection. Am J Pathol 2004;164:49-57.
112. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A: TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005; 202: 1715-1724.
113. Holscher C, Reiling N, Schaible UE, Holscher A, Bathmann C, Korbel D, Lenz I, Sonntag T, Kroger S, Akira S, Mossmann H, Kirschning CJ, Wagner H, Freudenberg M, Ehlers S: Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2,-4 and-9. Eur J Immunol 2008;38:680-694.
114. Blander JM, Medzhitov R: Regulation of phagosome maturation by signals from Toll-like receptors. Science 2004;304:1014-1018.
115. Ray JC, Flynn JL, Kirschner DE: Synergy between individual TNF-dependent functions determines granuloma performance for controlling Myco-bacterium tuberculosis infection. J Immunol 2009; 182:3706-3717.
116. Lucas R, Tacchini-Cottier F, Guler R, Vesin D, Jemelin S, Olleros ML, Marchal G, Browning JL, Vassalli P, Garcia I: A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection. Eur J Immunol 1999;29:4002-4010.
117. Ehlers S, Holscher C, Scheu S, Tertilt C, Hehlgans T, Suwinski J, Endres R, Pfeffer K: The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Myco-bacterium tuberculosis and Listeria monocytogenes. J Immunol 2003;170:5210-5218.
118. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase dis-integrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733.
119. Decker T, Lohmann-Matthes ML, Gifford GE: Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 1987;138:957-962.
120. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
121. Torres D, Janot L, Quesniaux VF, Grivennikov SI, Maillet I, Sedgwick JD, Ryffel B, Erard F: Membrane tumor necrosis factor confers partial protection to listeria infection. Am J Pathol 2005;167:1677-1687.
122. Fremond C, Allie N, Dambuza I, Grivennikov SI, Yeremeev V, Quesniaux VF, Jacobs M, Ryffel B: Membrane TNF confers protection to acute myco-bacterial infection. Respir Res 2005;6:136.
123. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ: Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005;174:4852-4859.
124. Dambuza I, Allie N, Fick L, Johnston N, Fremond C, Mitchell J, Quesniaux VF, Ryffel B, Jacobs M: Efficacy of membrane TNF mediated host resistance is dependent on mycobacterial virulence. Tuberculosis (Edinb) 2008;88:221-234.
125. Allie N, Alexopoulou L, Quesniaux VJ, Fick L, Kranidioti K, Kollias G, Ryffel B, Jacobs M: Protective role of membrane tumour necrosis factor in the host's resistance to mycobacterial infection. Immunology 2008;125:522-534.
126. Wallis RS: Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-611.
127. Keane J, Gershon S, Wise R P, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
128. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM: Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-299.
129. Keane J: TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005;44:714-720.
130. Wallis RS, Broder M, Wong J, Lee A, Hoq L: Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005;(suppl 3):S194-S198.
131. Flynn JL: Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 2006;8:1179-1188.
132. Botha T, Ryffel B: Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 2002; 107:350-357.
133. Flynn JL, Chan J: Tuberculosis: latency and reactivation. Infect Immun 2001;69:4195-4201.
134. Botha T, Ryffel B: Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003; 171:3110-3118.
135. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, Chan J, Flynn JL: Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007;195:1643-1650.
136. Marino S, Sud D, Plessner H, Lin PL, Chan J, Flynn JL, Kirschner DE: Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol 2007;3:1909-1924.
137. Steed PM, Tansey MG, Zalevsky J, et al: Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003;301:1895-1898.
138. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE: Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007; 179: 1872-1883.
139. Olleros ML, Vesin D, Lambou AF, Janssens J P, Ryffel B, Rose S, Fremond C, Quesniaux VF, Szymkowski DE, Garcia I: Dominant-negative tumor necrosis factor protects from Mycobacterium bovis bacillus Calmette-Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Infect Dis 2009;199:1053-1063.
140. Spohn G, Guler R, Johansen P, Keller I, Jacobs M, Beck M, Rohner F, Bauer M, Dietmeier K, Kundig TM, Jennings GT, Brombacher F, Bachmann MF: A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 2007;178:7450-7457.